Profound and controllable anticoagulation is essential during a large number of clinical procedures including percutaneous and surgical revascularization procedures (PCI and CABG), aortic surgery and other vascular interventions. Immediate anticoagulation therapy is also required in a variety of thrombotic diseases such as acute coronary syndromes, pulmonary embolism or deep vein thrombosis. Significant risks and side effects of all of these interventions and therapies include profound bleeding or thrombosis leading to cerebrovascular or cardiovascular compromise. The clinical and financial implications of these outcomes can be profound and are associated with prolonged hospitalization, reduced quality of life, and increased health-care resource utilization. The proposed work extends the basic discoveries of novel therapeutic anticoagulant aptamer/antidote pairs. We believe that a crucial next step in the translation of these agents to clinical practice is the testing in predictive in vitro and animal models such as those we will employ in this project. The proposed work will reveal whether this innovative therapeutic strategy can provide superior anticoagulation in prothrombotic environments, while avoiding undesired effects such as bleeding, platelet dysfunction, systemic inflammation and impaired wound healing.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HL112307-01
Application #
8391971
Study Section
Special Emphasis Panel (ZHL1-CSR-C (F1))
Project Start
Project End
Budget Start
2012-05-15
Budget End
2013-04-30
Support Year
1
Fiscal Year
2012
Total Cost
$315,133
Indirect Cost
$102,385
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Fager, A M; Machlus, K R; Ezban, M et al. (2018) Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity. J Thromb Haemost 16:1817-1829
Nimjee, Shahid M; White, Rebekah R; Becker, Richard C et al. (2017) Aptamers as Therapeutics. Annu Rev Pharmacol Toxicol 57:61-79
Lee, Jaewoo; Lee, Youngju; Xu, Li et al. (2017) Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. Mol Ther 25:1295-1305
Lee, Jaewoo; Jackman, Jennifer G; Kwun, Jean et al. (2017) Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. Biomaterials 120:94-102
Hoffman, Maureane; Monroe, Dougald M (2017) Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. Arterioscler Thromb Vasc Biol 37:1812-1818
Lee, Youngju; Urban, Johannes H; Xu, Li et al. (2016) 2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors. Nucleic Acid Ther 26:173-82
Soule, Erin E; Bompiani, Kristin M; Woodruff, Rebecca S et al. (2016) Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. Nucleic Acid Ther 26:1-9
Ganson, Nancy J; Povsic, Thomas J; Sullenger, Bruce A et al. (2016) Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol 137:1610-1613.e7
Woodruff, Rebecca S; Sullenger, Bruce A (2015) Modulation of the Coagulation Cascade Using Aptamers. Arterioscler Thromb Vasc Biol 35:2083-91
Bompiani, Kristin M; Lohrmann, Jens L; Pitoc, George A et al. (2014) Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chem Biol 21:935-44